Members get access to detailed formulation comparisons, B12 monitoring templates, and personalized protocol recommendations that account for individual risk factors most resources simply ignore
Both are injectable peptide-based therapies targeting multiple hormonal pathways cagrilintide as a long-acting amylin analogue, and retatrutide as a triple receptor agonist acting on GLP-1, GIP, and glucagon receptors
Diet companies making promises that play on customers desires, fears, and anxieties is nothing new, of course
The systemic exposure is simply too low to drive a meaningful pharmacokinetic interaction
Because symptoms of drug reactions can mimic other conditions, figuring out the exact cause isnt always easy
The SURMOUNT-1 trial found that visceral fat mass decreased by 40.1% with tirzepatide compared to just 7.3% with placebo